Singapore, Jan. 14 -- US-based Rakuten Medical, Inc. and South Korea's Lotte Biologics have signed a biopharmaceutical contract manufacturing agreement duringthe J.P. Morgan Healthcare Conferencein San Francisco to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox(R)platform-based photoimmunotherapy.

Under the agreement, Lotte Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supportingRakuten Medical's global clinical development and future commercialization.

Rakuten Medical's proprietary photoimmunotherapy technology is designed to selectively target cells in solid tumours, bycombining cell-targeting moieties, such as ant...